Combination Treatment May Improve Safety and Efficacy for Severe Agitation in Drug Overdoses

Combination treatment could be safer, more effective for drug overdoses involving severe agitation Researchers at Marshall University are investigating a new approach to managing severe agitation in patients experiencing drug overdoses, particularly those involving stimulants like methamphetamine or cocaine combined with opioids. Their preclinical study explores the use of dexmedetomidine, either alone or in combination with ketamine, as an alternative to current standard treatments. Current standard care for severe agitation often relies on benzodiazepines such as Valium. However, these medications can suppress breathing, posing significant risks when opioids are also present in the system—a common scenario in polysubstance use. This combination increases the likelihood of respiratory depression, which can be fatal. The Marshall research team, led by Michael Hambuchen, PharmD, PhD, from the School of Pharmacy, and Todd Davies, PhD, from the Joan C. Edwards School of Medicine, tested dexmedetomidine-based regimens in preclinical models. Their findings indicate that both high-dose dexmedetomidine alone and a combination of low-dose dexmedetomidine with ketamine effectively controlled methamphetamine-induced agitation in animal models. Notably, the combination therapy produced deeper initial sedation with fewer intense side effects compared to high-dose dexmedetomidine alone. Dexmedetomidine is particularly suited for this clinical context given that it provides sedation without compromising respiratory function, even when opioids are present. “Dexmedetomidine is uniquely suited to sedation in this clinical scenario as it doesn’t impair breathing, even with opioids present,” Davies said. “We are hoping that this will grow a tool for clinical care.” The study was published in the Journal of Pharmacy of Pharmaceutical Sciences. For further information, Michael Hambuchen can be contacted at 304-696-7297. This research addresses a growing necessitate for safer sedation strategies amid rising rates of polysubstance overdose. By avoiding respiratory suppression, dexmedetomidine-based regimens offer a promising avenue for managing severe agitation without exacerbating the life-threatening risks associated with opioid co-use.